Emergex Vaccines is a privately held company focusing on the development of medicines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen infected cells. Their vaccines elicit different responses than antibody producing vaccines which are associated with antibody dependent enhancement (ADE) complications.
They work on addressing some of the world’s most immediate health threats, including viral diseases such as Dengue Fever, Zika, Ebola, pandemic Flu, as well as serious intra-cellular bacterial infections.
Skills & Results
Emergex needed extra space for their vaccine R&D work and chose the adjacent unit to their existing facility. We opened the separating wall and connected the two units by creating a new corridor. The new space includes CL2 biology labs with tissue culture rooms, liquid nitrogen storage, and analytics. In addition, the facility needed installation of laboratory furniture, external gas storage and supply, provision of a 3-phase power supply.
The project included ancillary support with GMP areas and relocation, as well as new flooring and associated works in the upper floor office areas.
Photo Credit: Gary Mills, Saw Mill Films